Non-dopaminergic treatments in development for Parkinson's disease (Q37291597)

19 August 2017

1 reference

title

Non-dopaminergic treatments in development for Parkinson's disease (English)

1 reference

19 August 2017

1 reference

1 reference

3

Anthony E Lang

1 reference

19 August 2017

1

Susan H Fox

1 reference

19 August 2017

2

Jonathan M Brotchie

1 reference

19 August 2017

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

927-938

1 reference

Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Beating a dead horse: dopamine and Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Non-motor symptoms of Parkinson's disease: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The neuropathologic basis of different clinical subgroups of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Antidepressant studies in Parkinson's disease: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Systematic review of antidepressant therapies in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Depression rating scales in Parkinson's disease: critique and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Safinamide: from molecular targets to a new anti-Parkinson drug

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Long-term follow-up of impulse control disorders in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Compulsive drug use linked to sensitized ventral striatal dopamine transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Acamprosate for the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Sleep disorders in Parkinson's disease: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Hypocretin (orexin) cell loss in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Adenosine and sleep-wake regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The role of histamine and the tuberomamillary nucleus in the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Modafinil increases histamine release in the anterior hypothalamus of rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Dysautonomia in Parkinson's disease: neurocardiological abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Management of neurogenic orthostatic hypotension: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Gastrointestinal dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Nondopaminergic mechanisms in levodopa-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Improvement of motor function in early Parkinson disease by safinamide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Targeting adenosine A2A receptors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Zonisamide has beneficial effects on Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Subthalamic GAD gene therapy in a Parkinson's disease rat model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Neural substrates linking balance control and anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Glutamate receptors and Parkinson's disease: opportunities for intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Buspirone in levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Placebo influences on dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

The progression of Parkinson disease: a hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970214-X

7 January 2021

10.1016/S1474-4422(08)70214-X

Identifiers

DOI

1 reference

19 August 2017

1 reference